{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:17:41Z","timestamp":1785799061054,"version":"3.56.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s13555-023-01087-8","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T10:02:16Z","timestamp":1704794536000},"page":"271-284","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A Review of the Diagnostic and Therapeutic Gaps in Rosacea Management: Consensus Opinion"],"prefix":"10.1007","volume":"14","author":[{"given":"James","family":"Del Rosso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev","family":"Chavda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Phillipe","family":"York","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Harper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firas George","family":"Hougeir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Mark","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Noor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Schlesinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,9]]},"reference":[{"issue":"6","key":"1087_CR1","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.jaad.2020.01.077","volume":"82","author":"D Thiboutot","year":"2020","unstructured":"Thiboutot D, Anderson R, Cook-Bolden F, Draelos Z, Gallo RL, Granstein RD, et al. Standard management options for rosacea: the 2019 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2020;82(6):1501\u201310. https:\/\/doi.org\/10.1016\/j.jaad.2020.01.077.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1087_CR2","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/bjd.16481","volume":"179","author":"L Gether","year":"2018","unstructured":"Gether L, Overgaard LK, Egeberg A, Thyssen JP. Incidence and prevalence of rosacea: a systematic review and meta-analysis. Br J Dermatol. 2018;179(2):282\u20139. https:\/\/doi.org\/10.1111\/bjd.16481.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1087_CR3","doi-asserted-by":"publisher","DOI":"10.1080\/19381980.2017.1361574","volume":"9","author":"BM Rainer","year":"2017","unstructured":"Rainer BM, Kang S, Chien AL. Rosacea: epidemiology, pathogenesis, and treatment. Dermatoendocrinol. 2017;9(1): e1361574. https:\/\/doi.org\/10.1080\/19381980.2017.1361574.","journal-title":"Dermatoendocrinol"},{"issue":"5","key":"1087_CR4","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1111\/bjd.18420","volume":"182","author":"M Schaller","year":"2020","unstructured":"Schaller M, Almeida LMC, Bewley A, Cribier B, Del Rosso J, Dlova NC, et al. Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea COnsensus 2019 panel. Br J Dermatol. 2020;182(5):1269\u201376. https:\/\/doi.org\/10.1111\/bjd.18420.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1087_CR5","first-page":"234","volume":"92","author":"JQ Del Rosso","year":"2013","unstructured":"Del Rosso JQ, Thiboutot D, Gallo R, Webster G, Tanghetti E, Eichenfield L, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 1: a status report on the disease state, general measures, and adjunctive skin care. Cutis. 2013;92(5):234\u201340.","journal-title":"Cutis"},{"issue":"6","key":"1087_CR6","first-page":"17","volume":"12","author":"JQ Del Rosso","year":"2019","unstructured":"Del Rosso JQ, Tanghetti E, Webster G, Stein Gold L, Thiboutot D, Gallo RL. Update on the management of rosacea from the American Acne & Rosacea Society (AARS). J Clin Aesthet Dermatol. 2019;12(6):17\u201324.","journal-title":"J Clin Aesthet Dermatol"},{"key":"1087_CR7","unstructured":"Steinhoff, M, Harper J, Gieler U, Tan J. Beyond the Visible: Rosacea and psoriasis of the face 2020. https:\/\/hosted.bmj.com\/rosacea\/assets\/beyond-the-visible-rosacea-and-psoriasis-of-the-face.pdf. Accessed 18 May 2023."},{"issue":"2","key":"1087_CR8","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s00266-011-9802-0","volume":"36","author":"D Lazzeri","year":"2012","unstructured":"Lazzeri D, Colizzi L, Licata G, Pagnini D, Proietti A, Al\u00ec G, et al. Malignancies within rhinophyma: report of three new cases and review of the literature. Aesthetic Plast Surg. 2012;36(2):396\u2013405. https:\/\/doi.org\/10.1007\/s00266-011-9802-0.","journal-title":"Aesthetic Plast Surg"},{"issue":"5","key":"1087_CR9","doi-asserted-by":"publisher","first-page":"855","DOI":"10.5114\/ada.2020.99367","volume":"38","author":"I Chlebicka","year":"2021","unstructured":"Chlebicka I, Stefaniak AA, Bieniek A, Matusiak \u0141, Wo\u017aniak Z, Szepietowski JC. Basal cell carcinoma within rhinophyma: coincidence or relationship? Postepy Dermatol Alergol. 2021;38(5):855\u20137. https:\/\/doi.org\/10.5114\/ada.2020.99367.","journal-title":"Postepy Dermatol Alergol"},{"issue":"1","key":"1087_CR10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3390\/jcm9010185","volume":"9","author":"YR Woo","year":"2020","unstructured":"Woo YR, Lee SH, Cho SH, Lee JD, Kim HS. Characterization and analysis of the skin microbiota in rosacea: Impact of systemic antibiotics. J Clin Med. 2020;9(1):185. https:\/\/doi.org\/10.3390\/jcm9010185.","journal-title":"J Clin Med"},{"issue":"6","key":"1087_CR11","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s13555-020-00458-9","volume":"10","author":"FMN Forton","year":"2020","unstructured":"Forton FMN. The pathogenic role of demodex mites in rosacea: a potential therapeutic target already in erythematotelangiectatic rosacea? Dermatol Ther (Heidelb). 2020;10(6):1229\u201353. https:\/\/doi.org\/10.1007\/s13555-020-00458-9.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"Pt 11","key":"1087_CR12","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1099\/jmm.0.048090-0","volume":"61","author":"S Jarmuda","year":"2012","unstructured":"Jarmuda S, O\u2019Reilly N, \u017baba R, Jakubowicz O, Szkaradkiewicz A, Kavanagh K. Potential role of demodex mites and bacteria in the induction of rosacea. J Med Microbiol. 2012;61(Pt 11):1504\u201310. https:\/\/doi.org\/10.1099\/jmm.0.048090-0.","journal-title":"J Med Microbiol"},{"issue":"3","key":"1087_CR13","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/j.1365-2133.2007.08028.x","volume":"157","author":"N Lacey","year":"2007","unstructured":"Lacey N, Delaney S, Kavanagh K, Powell FC. Mite-related bacterial antigens stimulate inflammatory cells in rosacea. Br J Dermatol. 2007;157(3):474\u201381. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.08028.x.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1087_CR14","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/j.1365-2133.2011.10746.x","volume":"166","author":"N O\u2019Reilly","year":"2012","unstructured":"O\u2019Reilly N, Bergin D, Reeves EP, McElvaney NG, Kavanagh K. Demodex-associated bacterial proteins induce neutrophil activation. Br J Dermatol. 2012;166(4):753\u201360. https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10746.x.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1087_CR15","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jaad.2003.05.005","volume":"50","author":"MV Dahl","year":"2004","unstructured":"Dahl MV, Ross AJ, Schlievert PM. Temperature regulates bacterial protein production: possible role in rosacea. J Am Acad Dermatol. 2004;50(2):266\u201372. https:\/\/doi.org\/10.1016\/j.jaad.2003.05.005.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1087_CR16","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/nm1616","volume":"13","author":"K Yamasaki","year":"2007","unstructured":"Yamasaki K, Nardo AD, Bardan A, Murakami M, Ohtake T, Coda A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007;13(8):975\u201380. https:\/\/doi.org\/10.1038\/nm1616.","journal-title":"Nat Med"},{"issue":"8","key":"1087_CR17","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/exd.13143","volume":"26","author":"AD Holmes","year":"2017","unstructured":"Holmes AD, Steinhoff M. Integrative concepts of rosacea pathophysiology, clinical presentation and new therapeutics. Exp Dermatol. 2017;26(8):659\u201367. https:\/\/doi.org\/10.1111\/exd.13143.","journal-title":"Exp Dermatol"},{"issue":"1","key":"1087_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.35841\/cell-science.2.1.39-42","volume":"2","author":"KTM Chan","year":"2018","unstructured":"Chan KTM. Transient receptors potential (TRP) channels and neuroimmunology: mutation pathways of Rosacea. J Cell Sci Mut. 2018;2(1):39\u201342. https:\/\/doi.org\/10.35841\/cell-science.2.1.39-42.","journal-title":"J Cell Sci Mut"},{"issue":"2","key":"1087_CR19","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jdermsci.2022.11.004","volume":"108","author":"X Zhou","year":"2022","unstructured":"Zhou X, Su Y, Wu S, Wang H, Jiang R, Jiang X. The temperature-sensitive receptors TRPV4 and TRPM8 have important roles in the pruritus of rosacea. J Dermatol Sci. 2022;108(2):68\u201376. https:\/\/doi.org\/10.1016\/j.jdermsci.2022.11.004.","journal-title":"J Dermatol Sci"},{"issue":"4","key":"1087_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.5826\/dpc.0704a08","volume":"7","author":"E Weiss","year":"2017","unstructured":"Weiss E, Katta R. Diet and rosacea: the role of dietary change in the management of rosacea. Dermatol Pract Concept. 2017;7(4):31\u20137. https:\/\/doi.org\/10.5826\/dpc.0704a08.","journal-title":"Dermatol Pract Concept"},{"issue":"6","key":"1087_CR21","first-page":"531","volume":"7","author":"JQ Del Rosso","year":"2008","unstructured":"Del Rosso JQ, Baldwin H, Webster G, American Acne & Rosacea Society. American Acne & Rosacea Society rosacea medical management guidelines. J Drugs Dermatol. 2008;7(6):531\u20133.","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"1087_CR22","first-page":"277","volume":"92","author":"JQ Del Rosso","year":"2013","unstructured":"Del Rosso JQ, Thiboutot D, Gallo R, Webster G, Tanghetti E, Eichenfield LF, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 2: a status report on topical agents. Cutis. 2013;92(6):277\u201384.","journal-title":"Cutis"},{"issue":"1","key":"1087_CR23","first-page":"18","volume":"93","author":"JQ Del Rosso","year":"2014","unstructured":"Del Rosso JQ, Thiboutot D, Gallo R, Webster G, Tanghetti E, Eichenfield LF, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 3: a status report on systemic therapies. Cutis. 2014;93(1):18\u201328.","journal-title":"Cutis"},{"issue":"2","key":"1087_CR24","first-page":"71","volume":"93","author":"E Tanghetti","year":"2014","unstructured":"Tanghetti E, Del Rosso JQ, Thiboutot D, Gallo R, Webster G, Eichenfield LF, et al. Consensus recommendations from the American acne & rosacea society on the management of rosacea, part 4: a status report on physical modalities and devices. Cutis. 2014;93(2):71\u20136.","journal-title":"Cutis"},{"issue":"3","key":"1087_CR25","first-page":"134","volume":"93","author":"JQ Del Rosso","year":"2014","unstructured":"Del Rosso JQ, Thiboutot D, Gallo R, Webster G, Tanghetti E, Eichenfield LF, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 5: a guide on the management of rosacea. Cutis. 2014;93(3):134\u20138.","journal-title":"Cutis"},{"issue":"2","key":"1087_CR26","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/bjd.15173","volume":"176","author":"M Schaller","year":"2017","unstructured":"Schaller M, Almeida LMC, Bewley A, Cribier B, Dlova NC, Kautz G, et al. Rosacea treatment update: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol. 2017;176(2):465\u201371. https:\/\/doi.org\/10.1111\/bjd.15173.","journal-title":"Br J Dermatol"},{"issue":"3 Suppl","key":"1087_CR27","first-page":"1","volume":"91","author":"JQ Del Rosso","year":"2013","unstructured":"Del Rosso JQ, Gallo RL, Tanghetti E, Webster G, Thiboutot D. An evaluation of potential correlations between pathophysiologic mechanisms, clinical manifestations, and management of rosacea. Cutis. 2013;91(3 Suppl):1\u20138.","journal-title":"Cutis"},{"issue":"3","key":"1087_CR28","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/bjd.16815","volume":"179","author":"J Tan","year":"2018","unstructured":"Tan J, Berg M, Gallo RL, Del Rosso JQ. Applying the phenotype approach for rosacea to practice and research. Br J Dermatol. 2018;179(3):741\u20136. https:\/\/doi.org\/10.1111\/bjd.16815.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1087_CR29","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/bjd.17590","volume":"181","author":"EJ van Zuuren","year":"2019","unstructured":"van Zuuren EJ, Fedorowicz Z, Tan J, van der Linden MMD, Arents BWM, Carter B, et al. Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments. Br J Dermatol. 2019;181(1):65\u201379. https:\/\/doi.org\/10.1111\/bjd.17590.","journal-title":"Br J Dermatol"},{"issue":"7","key":"1087_CR30","first-page":"838","volume":"11","author":"ND Bhatia","year":"2012","unstructured":"Bhatia ND, Del Rosso JQ. Optimal management of papulopustular rosacea: rationale for combination therapy. J Drugs Dermatol. 2012;11(7):838\u201344.","journal-title":"J Drugs Dermatol"},{"issue":"9","key":"1087_CR31","first-page":"909","volume":"16","author":"L Stein Gold","year":"2017","unstructured":"Stein Gold L, Papp K, Lynde C, Lain E, Gooderham M, Johnson S, et al. Treatment of rosacea with concomitant use of topical ivermectin 1% cream and brimonidine 0.33% gel: a randomized, vehicle-controlled study. J Drugs Dermatol. 2017;16(9):909\u201316.","journal-title":"J Drugs Dermatol"},{"issue":"9","key":"1087_CR32","first-page":"22","volume":"4","author":"JQ Del Rosso","year":"2011","unstructured":"Del Rosso JQ, Levin J. The clinical relevance of maintaining the functional integrity of the stratum corneum in both healthy and disease-affected skin. J Clin Aesthet Dermatol. 2011;4(9):22\u201342.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"1","key":"1087_CR33","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/lsm.23253","volume":"53","author":"EA Tanghetti","year":"2021","unstructured":"Tanghetti EA, Goldberg DJ, Dover JS, Geronemus RG, Bai Z, Alvandi N, et al. Oxymetazoline and energy-based therapy in patients with rosacea: evaluation of the safety and tolerability in an open-label, interventional study. Lasers Surg Med. 2021;53(1):55\u201365. https:\/\/doi.org\/10.1002\/lsm.23253.","journal-title":"Lasers Surg Med"},{"issue":"6","key":"1087_CR34","doi-asserted-by":"publisher","first-page":"574","DOI":"10.36849\/JDD.6838","volume":"21","author":"A Alexis","year":"2022","unstructured":"Alexis A, Woolery-Lloyd H, Andriessen A, Desai S, Han G, Rodriguez D. Improving rosacea outcomes in skin of color patients: a review on the nuances in the treatment and the use of cleansers and moisturizers. J Drugs Dermatol. 2022;21(6):574\u201380. https:\/\/doi.org\/10.36849\/JDD.6838.","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"1087_CR35","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1111\/j.1365-2133.2004.05985.x","volume":"150","author":"T Dirschka","year":"2004","unstructured":"Dirschka T, Tronnier H, F\u00f6lster-Holst R. Epithelial barrier function and atopic diathesis in rosacea and perioral dermatitis. Br J Dermatol. 2004;150(6):1136\u201341. https:\/\/doi.org\/10.1111\/j.1365-2133.2004.05985.x.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1087_CR36","first-page":"5","volume":"22","author":"C Zip","year":"2017","unstructured":"Zip C. The role of skin care in optimizing treatment of acne and rosacea. Skin Therapy Lett. 2017;22(3):5\u20137.","journal-title":"Skin Therapy Lett"},{"issue":"6 Suppl 1","key":"1087_CR37","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1016\/j.jaad.2013.04.040","volume":"69","author":"G Webster","year":"2013","unstructured":"Webster G, Schaller M. Ocular rosacea: a dermatologic perspective. J Am Acad Dermatol. 2013;69(6 Suppl 1):S42\u20133. https:\/\/doi.org\/10.1016\/j.jaad.2013.04.040.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1087_CR38","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1186\/s13063-022-06948-9","volume":"23","author":"H Mahmud","year":"2022","unstructured":"Mahmud H, Keenan JD, Gonzales J, Schallhorn J, Chan M, Arnold B, et al. Ocular Rosacea microBiome Study (ORBS)-sub-microbial versus antibiotic dosing of doxycycline versus placebo in treatment of symptomatic ocular rosacea: study protocol for a parallel-arm randomized clinical trial. Trials. 2022;23(1):1033. https:\/\/doi.org\/10.1186\/s13063-022-06948-9.","journal-title":"Trials"},{"issue":"1","key":"1087_CR39","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1001\/archderm.133.1.49","volume":"133","author":"MJ Quarterman","year":"1997","unstructured":"Quarterman MJ, Johnson DW, Abele DC, Lesher JL Jr, Hull DS, Davis LS. Ocular rosacea. Signs, symptoms, and tear studies before and after treatment with doxycycline. Arch Dermatol. 1997;133(1):49\u201354. https:\/\/doi.org\/10.1001\/archderm.133.1.49.","journal-title":"Arch Dermatol"},{"issue":"3","key":"1087_CR40","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/ICO.0000000000000051","volume":"33","author":"B Sobolewska","year":"2014","unstructured":"Sobolewska B, Doycheva D, Deuter C, Pfeffer I, Schaller M, Zierhut M. Treatment of ocular rosacea with once-daily low-dose doxycycline. Cornea. 2014;33(3):257\u201360. https:\/\/doi.org\/10.1097\/ICO.0000000000000051.","journal-title":"Cornea"},{"issue":"3","key":"1087_CR41","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3980\/j.issn.2222-3959.2015.03.19","volume":"8","author":"A Arman","year":"2015","unstructured":"Arman A, Demirseren DD, Takmaz T. Treatment of ocular rosacea: comparative study of topical cyclosporine and oral doxycycline. Int J Ophthalmol. 2015;8(3):544\u20139. https:\/\/doi.org\/10.3980\/j.issn.2222-3959.2015.03.19.","journal-title":"Int J Ophthalmol"},{"issue":"6","key":"1087_CR42","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1080\/09273948.2020.1727531","volume":"29","author":"B Sobolewska","year":"2021","unstructured":"Sobolewska B, Doycheva D, Deuter C, Schaller M, Zierhut M. Efficacy of topical ivermectin for the treatment of cutaneous and ocular rosacea. Ocul Immunol Inflamm. 2021;29(6):1137\u201341. https:\/\/doi.org\/10.1080\/09273948.2020.1727531.","journal-title":"Ocul Immunol Inflamm"},{"issue":"6","key":"1087_CR43","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1007\/s13555-021-00607-8","volume":"11","author":"V Yepuri","year":"2021","unstructured":"Yepuri V, Patil AD, Fritz K, Salavastru C, Kroumpouzos G, Nistic\u00f2 SP, et al. Light-based devices for the treatment of facial erythema and telangiectasia. Dermatol Ther (Heidelb). 2021;11(6):1879\u201387. https:\/\/doi.org\/10.1007\/s13555-021-00607-8.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1087_CR44","first-page":"37","volume":"1","author":"AF Taub","year":"2008","unstructured":"Taub AF, DeVita EC. Successful treatment of erythematotelangiectatic rosacea with pulsed light and radiofrequency. J Clin Aesthet Dermatol. 2008;1(1):37\u201340.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"3","key":"1087_CR45","first-page":"42","volume":"14","author":"A Luque","year":"2021","unstructured":"Luque A, Rojas AP, Ortiz-Florez A, Perez-Bernal J. Botulinum toxin: an effective treatment for flushing and persistent erythema in rosacea. J Clin Aesthet Dermatol. 2021;14(3):42\u20135.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"1","key":"1087_CR46","doi-asserted-by":"publisher","first-page":"20","DOI":"10.18773\/austprescr.2018.004","volume":"41","author":"AL Rivero","year":"2018","unstructured":"Rivero AL, Whitfeld M. An update on the treatment of rosacea. Aust Prescr. 2018;41(1):20\u20134. https:\/\/doi.org\/10.18773\/austprescr.2018.004.","journal-title":"Aust Prescr"},{"issue":"6","key":"1087_CR47","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.jaad.2018.01.027","volume":"78","author":"ZD Draelos","year":"2018","unstructured":"Draelos ZD, Gold MH, Weiss RA, Baumann L, Grekin SK, Robinson DM, et al. Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the 52-week open label REVEAL trial. J Am Acad Dermatol. 2018;78(6):1156\u201363. https:\/\/doi.org\/10.1016\/j.jaad.2018.01.027.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"1087_CR48","first-page":"E60","volume":"15","author":"M Schaller","year":"2022","unstructured":"Schaller M, Tan J, Webster G. How to optimize rosacea treatment for better patient outcomes: An opinion piece. J Clin Aesthet Dermatol. 2022;15(7):E60\u20132.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"6","key":"1087_CR49","doi-asserted-by":"publisher","first-page":"451","DOI":"10.5021\/ad.22.093","volume":"34","author":"JS Kim","year":"2022","unstructured":"Kim JS, Seo BH, Cha DR, Suh HS, Choi YS. Maintenance of remission after oral metronidazole add-on therapy in rosacea treatment: a retrospective, comparative study. Ann Dermatol. 2022;34(6):451\u201360. https:\/\/doi.org\/10.5021\/ad.22.093.","journal-title":"Ann Dermatol"},{"key":"1087_CR50","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2021-11-1","author":"K Maliyar","year":"2022","unstructured":"Maliyar K, Abdulla SJ. Dermatology: how to manage rosacea in skin of colour. Drugs Context. 2022. https:\/\/doi.org\/10.7573\/dic.2021-11-1.","journal-title":"Drugs Context."},{"key":"1087_CR51","unstructured":"Epsolay Prescribing Information. Galderma. 2022. https:\/\/www.galderma.com\/us\/sites\/default\/files\/2022-03\/Epsolay_PI.pdf. Accessed 18 May 2023."},{"issue":"6","key":"1087_CR52","first-page":"252","volume":"93","author":"WE Pace","year":"1965","unstructured":"Pace WE. A benzoyl peroxide-sulfur cream for acne vulgaris. Can Med Assoc J. 1965;93(6):252\u20134.","journal-title":"Can Med Assoc J"},{"issue":"1","key":"1087_CR53","doi-asserted-by":"publisher","first-page":"54","DOI":"10.36849\/JDD.7150","volume":"22","author":"H Baldwin","year":"2023","unstructured":"Baldwin H, Elewski B, Hougeir F, Yamauchi P, Levy-Hacham O, Hamil K, et al. Sixty years of benzoyl peroxide use in dermatology. J Drugs Dermatol. 2023;22(1):54\u20139. https:\/\/doi.org\/10.36849\/JDD.7150.","journal-title":"J Drugs Dermatol"},{"issue":"8","key":"1087_CR54","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/j.1346-8138.2004.tb00566.x","volume":"31","author":"S Ozt\u00fcrkcan","year":"2004","unstructured":"Ozt\u00fcrkcan S, Ermertcan AT, Sahin MT, Af\u015far FS. Efficiency of benzoyl peroxide-erythromycin gel in comparison with metronidazole gel in the treatment of acne rosacea. J Dermatol. 2004;31(8):610\u20137. https:\/\/doi.org\/10.1111\/j.1346-8138.2004.tb00566.x.","journal-title":"J Dermatol"},{"issue":"5","key":"1087_CR55","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/j.1365-4632.2004.02283.x","volume":"43","author":"D Breneman","year":"2004","unstructured":"Breneman D, Savin R, VadePol C, Vamvakias G, Levy S, Leyden J. Double-blind, randomized, vehicle-controlled clinical trial of once-daily benzoyl peroxide\/clindamycin topical gel in the treatment of patients with moderate to severe rosacea. Int J Dermatol. 2004;43(5):381\u20137. https:\/\/doi.org\/10.1111\/j.1365-4632.2004.02283.x.","journal-title":"Int J Dermatol"},{"key":"1087_CR56","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.jcis.2020.06.114","volume":"579","author":"M Erlich","year":"2020","unstructured":"Erlich M, Arie T, Koifman M, Talmon Y. Structure elucidation of silica-based core-shell microencapsulated drugs for topical applications by cryogenic scanning electron microscopy. J Colloid Interface Sci. 2020;579:778\u201385. https:\/\/doi.org\/10.1016\/j.jcis.2020.06.114.","journal-title":"J Colloid Interface Sci"},{"key":"1087_CR57","unstructured":"Bhatia N et al. Efficacy and safety of microencapsulated benzoyl peroxide (E-BPO) cream, 5% in papulopustular rosacea: results from two phase 3, vehicle-controlled trials. https:\/\/ir.sol-gel.com\/static-files\/efbfefd1-93fb-405b-9dca-011df6c438e9. Accessed 18 May 2023."},{"key":"1087_CR58","doi-asserted-by":"crossref","unstructured":"Bhatia N, et al. Long-term efficacy and safety of benzoyl peroxide cream, 5% prepared with microencapsulation in papulopustular rosacea: results from an extension of two phase 3, vehicle-controlled trials. In: Poster Presented at Maui Derm Live Dermatology CME Conference 2021, Maui, Hawaii.","DOI":"10.25251\/skin.5.supp.25"},{"issue":"5","key":"1087_CR59","first-page":"36","volume":"15","author":"LJ Green","year":"2022","unstructured":"Green LJ, Lain E. Enhancing topical pharmacotherapy for acne and rosacea: vehicle choices and outcomes. J Clin Aesthet Dermatol. 2022;15(5):36\u201340.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"2","key":"1087_CR60","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1021\/cr100161x","volume":"111","author":"R Ciriminna","year":"2011","unstructured":"Ciriminna R, Sciortino M, Alonzo G, de Schrijver A, Pagliaro M. From molecules to systems: sol-gel microencapsulation in silica-based materials. Chem Rev. 2011;111(2):765\u201389. https:\/\/doi.org\/10.1021\/cr100161x.","journal-title":"Chem Rev"},{"key":"1087_CR61","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jconrel.2013.12.028","volume":"178","author":"PL Lam","year":"2014","unstructured":"Lam PL, Gambari R. Advanced progress of microencapsulation technologies: in vivo and in vitro models for studying oral and transdermal drug deliveries. J Control Release. 2014;178:25\u201345. https:\/\/doi.org\/10.1016\/j.jconrel.2013.12.028.","journal-title":"J Control Release"},{"issue":"1","key":"1087_CR62","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/jidsymp.2011.4","volume":"15","author":"K Yamasaki","year":"2011","unstructured":"Yamasaki K, Gallo RL. Rosacea as a disease of cathelicidins and skin innate immunity. J Investig Dermatol Symp Proc. 2011;15(1):12\u20135. https:\/\/doi.org\/10.1038\/jidsymp.2011.4.","journal-title":"J Investig Dermatol Symp Proc"},{"key":"1087_CR63","doi-asserted-by":"crossref","unstructured":"Micali G, et al. 42109\u2014clinical and erythema-directed imaging evaluation of inflamed rhinophyma with topical ivermectin: a case series. In: Poster Presented at American Academy of Dermatology 2023, New Orleans, U.S.","DOI":"10.1016\/j.jaad.2023.07.542"},{"key":"1087_CR64","unstructured":"ZILXI Prescribing Information. VYNE Therapeutics Inc; 2020. https:\/\/zilxi.com\/sites\/default\/files\/documents\/prescribing-information.pdf. Accessed 7 June 2023."},{"issue":"5","key":"1087_CR65","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/j.jaad.2020.01.043","volume":"82","author":"L Stein Gold","year":"2020","unstructured":"Stein Gold L, Del Rosso JQ, Kircik L, Bhatia ND, Hooper D, Nahm WK, et al. Minocycline 1.5% foam for the topical treatment of moderate to severe papulopustular rosacea: results of 2 phase 3, randomized, clinical trials. J Am Acad Dermatol. 2020;82(5):1166\u201373. https:\/\/doi.org\/10.1016\/j.jaad.2020.01.043.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1087_CR66","first-page":"14","volume":"14","author":"JQ Del Rosso","year":"2021","unstructured":"Del Rosso JQ, Webster G, Weiss JS, Bhatia ND, Stein Gold L, Kircik L. Nonantibiotic properties of tetracyclines in rosacea and their clinical implications. J Clin Aesthet Dermatol. 2021;14(8):14\u201321.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"4","key":"1087_CR67","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1067\/mjd.2002.120625","volume":"46","author":"J Wilkin","year":"2002","unstructured":"Wilkin J, Dahl M, Detmar M, Drake L, Feinstein A, Odom R, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46(4):584\u20137. https:\/\/doi.org\/10.1067\/mjd.2002.120625.","journal-title":"J Am Acad Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-01087-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-023-01087-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-01087-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T18:19:43Z","timestamp":1708712383000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-023-01087-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,9]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["1087"],"URL":"https:\/\/doi.org\/10.1007\/s13555-023-01087-8","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,9]]},"assertion":[{"value":"12 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All panel members received honoraria from Galderma for participating in this project. James Del Rosso has served as a research investigator, consultant and\/or speaker for Almirall, Bausch Health (Ortho Dermatology), BiopharmX, Dermata, Dr. Reddy, EPI Health, Evommune, Ferndale, Galderma, JEM Health, LaRoche Posay, LEO Pharma, L\u2019Or\u00e9al, Mayne Pharma, Primus, Sente, Sol\u2013Gel, Sonoma, Sun Pharma, and Vyne Therapeutics (Foamix). Hilary Baldwin has acted as an investigator, consultant, and\/or speaker for Almirall, Bausch Health, Cassiopeia, EPI Health, Galderma, La Roche-Posay, L\u2019Or\u00e9al, Mayne Pharma, Sol\u2013Gel, Sun Pharma, and Vyne. Neal Bhatia has served as advisor, consultant, and\/or investigator for Abbvie, Almirall, Arcutis, Arena, Biofrontera, BMS, BI, Brickell, Dermavant, EPI Health, Ferndale, Galderma, Genentech, InCyte, ISDIN, J&J, LaRoche-Posay, Leo, Lilly, Mayne, Novartis, Ortho, Pfizer, P&G, Regeneron, Sanofi, Stemline, SunPharma, Verrica, and Vyne. Rajeev Chavda and Jean Phillipe York are employees of Galderma. Julie Harper has received honoraria from Almirall, Bausch Health (Ortho Dermatologics), BiopharmX, Cassiopeia, Cutanea, Dermira, EPI Health, Galderma, LaRoche Posay, SolGel, Sun Pharma, and Vyne Therapeutics (Foamix). Firas George Hougeir has served as an investigator, consultant, advisor and\/or speaker for Galderma, Abbvie, Aclaris, Almirall, Amgen, Arcutis, Dermavant, Intraderm, ISDIN, Janssen, LEO Pharma, Lilly, Menarini, Novartis, Orthodermatologics, Pfizer, Promius, Regeneron, Sanofi-Genzyme, UCB, and Verrica. J. Mark Jackson has received research, honoraria, and\/or consulting support from Abbvie, Arcuitis, BMS, Dermavant, Evommune, Galderma, Janssen, Lilly, Novartis, Pfizer, Sanofi\/Genzyme, and UCB. Omar Noor has worked as a consultant for Abbvie Inc., Almirall LLC, Amgen Inc., Galderma, Lilly USA, Ortho Dermatologics, Novartis Pharmaceuticals Corporation, Pfizer Inc., Procter & Gamble Ventures, Regeneron Pharmaceuticals Inc., and Sanofi Genzyme. David Rodriguez has received honoraria, has consultancy agreements with, and\/or has served as a speaker for Allergan, Inc, Galderma, Genentech, LEO Pharma, and Merz. Todd Schlesinger has acted in a consulting, speaking or advisory capacity for AbbVie, Allergan, Almirall, Amgen, ASLAN Pharma, Arcutis, Biofrontera AG, Bristol Myers Squibb, Castle Biosciences, Cara Therapeutics, Celgene, CMS Aesthetics DCME, Concert Pharmaceuticals (now SUN), Lilly, Galderma, Genentech, Greenway Therapeutix (shareholder), Janssen, Kintor, MED Learning Group, Merz, MJH Associates, Nextphase Therapeutics, Novartis, Ortho Dermatologics, Pfizer, Pierre Fabre, Plasmed, Prolacta Bioscience, RBC, Regeneron, Sanofi Genzyme, SkinCeuticals\/L\u2019Or\u00e9al, Sisaf, SUN Pharma, UCB and Verrica. Jonathan Weiss has acted as an investigator\/advisor and\/or speaker for Almirall, Dr Reddy\u2019s, EPI Health, Foamix, Galderma, Novartis, and Ortho Derm.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. The patient presented in the case study has consented to their anonymized medical details, treatment plan, and patient photos to be published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}